These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3322358)

  • 21. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
    Smith CD; McKendry RJ
    Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.
    Wollersheim H; Thien T; Fennis J; van Elteren P; van 't Laar A
    Clin Pharmacol Ther; 1986 Aug; 40(2):219-25. PubMed ID: 3731684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
    Khan F; Coffman JD
    Circulation; 1994 Mar; 89(3):1183-8. PubMed ID: 8124805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon.
    Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA
    Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Cardiol; 1985 Jan; 55(3):154B-157B. PubMed ID: 3881908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome].
    Gross R; Galus K; Zajac S; Jedrasik M
    Wiad Lek; 2002; 55(1-2):29-34. PubMed ID: 12043312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Calcium antagonists for the treatment of Raynaud's phenomenon].
    Müller-Bühl U; Diehm C; Scheuermann W; Mörl H
    Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud's phenomenon.
    Holti G
    Curr Med Res Opin; 1979; 6(4):267-70. PubMed ID: 527352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.
    Miyazaki S; Miura K; Kasai Y; Abe K; Yoshinaga K
    Br Med J (Clin Res Ed); 1982 Jan; 284(6312):310-11. PubMed ID: 6174171
    [No Abstract]   [Full Text] [Related]  

  • 36. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Kelbaek H; Hartling OJ; Nielsen SL
    Am Heart J; 1986 Apr; 111(4):742-5. PubMed ID: 3513504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon.
    Belch JJ; Madhok R; Shaw B; Leiberman P; Sturrock RD; Forbes CD
    Lancet; 1985 May; 1(8439):1180-3. PubMed ID: 2860386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Hayward RA; Griffin MJ; Roath OS
    Angiology; 1989 Feb; 40(2):122-8. PubMed ID: 2644877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.